Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 380 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Antipsychotic Clear all

Conditions: Obesity
Interventions: CBT, educational; Behavioral · Other
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Schizophrenia
Interventions: ACP-103; Drug
Lead sponsor: ACADIA Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 11
States / cities: Cerritos, California • Garden Grove, California • Glendale, California + 7 more

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Valacyclovir, Placebo; Drug
Lead sponsor: Konasale Prasad; Other
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 2
States / cities: Detroit, Michigan • Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: Zicronapine open-label lead-in 10 mg daily, Zicronapine 10 mg daily, Zicronapine 20 mg once weekly, Zicronapine 30 mg once weekly, Zicronapine 45 mg once weekly; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 4
States / cities: Garden Grove, California • National City, California • San Diego, California + 1 more

Conditions: Schizophrenia
Interventions: SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 4
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Dayton, Ohio + 1 more

Conditions: Bipolar Youth Treated With Second-generation Antipsychotics
Interventions: Omega, Placebo, Quetiapine fumarate; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 10 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Borderline Personality Disorder
Interventions: Caplyta, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psychoses
Interventions: Not listed
Lead sponsor: Genomas, Inc; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Hartford, Connecticut • Lexington, Kentucky

Conditions: Antipsychotic-induced Weight Gain (AIWG)
Interventions: Miricorlilant, Placebo; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 40
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Culver City, California + 33 more

Conditions: Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions: ziprasidone vs. aripiprazole, aripiprazole vs. ziprasidone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Major Depressive Disorder Without Psychotic Features
Interventions: Asenapine 5-20 mg daily, Placebo 1-4 tablets daily; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 5
States / cities: Augusta, Georgia • Durham, North Carolina • Greenville, North Carolina + 1 more

Conditions: Cocaine-Related Disorders, Substance-Related Disorders
Interventions: quetiapine; Drug
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Post-Traumatic Stress Disorder
Interventions: sertraline and risperidone; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Atlanta, Georgia • Charleston, South Carolina

Conditions: Schizophrenia, Sensory Gating
Interventions: Aripiprzole; Drug
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Schizophrenia
Interventions: Quetiapine; Drug
Lead sponsor: New Mexico VA Healthcare System; Federal
Eligibility: 18 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
Interventions: Valbenazine Oral Capsule; Drug
Lead sponsor: Stephen Ruedrich; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Schizophrenia
Interventions: Aripiprazole Lauroxil, Computerized cognitive and functional skills training; Drug · Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Parkinson Disease
Interventions: Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit); Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Schizophrenia
Interventions: Paliperidone palmitate 25 mg eq., Paliperidone palmitate 150 mg eq., Placebo, Paliperidone palmitate 100 mg eq.; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 652 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Anaheim, California • Cerritos, California • Escondido, California + 29 more

Conditions: Schizophrenia
Interventions: Org 24448, Placebo; Drug · Other
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 8
States / cities: Los Angeles, California • Catonsville, Maryland • Boston, Massachusetts + 4 more

Conditions: Schizophrenia
Interventions: SEP-363856; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 25
States / cities: Anaheim, California • Bellflower, California • Culver City, California + 19 more

Conditions: Parkinson's Disease Psychosis, Dementia With Lewy Bodies
Interventions: Pimavanserin, Quetiapine; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Not listed
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Schizophrenia, Type 2 Diabetes Mellitus
Interventions: Stayers, Switchers; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Bipolar Disorder
Interventions: Licarbazepine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 22
States / cities: Little Rock, Arkansas • Orange, California • Pico Rivera, California + 18 more

Search by objective public record fields.

Cognitive Behavioral Therapy for Obesity

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Systematic Evaluation of Antiviral Medication in Schizophrenia

Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

SGA-induced Metabolic Syndrome in Bipolar Youth

Caplyta in Borderline Personality Disorder

DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)

Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome

Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression

Quetiapine for Cocaine Use and Cravings

Risperidone Augmentation for PTSD

Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole

Schizophrenia Sensory Gating Deficit With Quetiapine

Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities

C-Cog in Early Course Schizophrenia Study

The Use of Sensory or Motor Cues Using Electrical Stimulation to Reduce Gait Freezing in Patients With Parkinson Disease

Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia

Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia

A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication

Comparing Antipsychotic Medications in LBD Over Time

Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder